Halo Pharma, Inc. provides pharmaceutical contract development and manufacturing services. It specializes in the development and commercialization of controlled substances, including drug products used for pain management and ADHD. The company has particular expertise in abuse deterrent technologies and complex IR/ER products. It offers commercial manufacturing services in various dosage forms and drug delivery platforms, including complex formulations, such as modified release tablets, capsules, topicals (sterile and non sterile), and oral solutions. The company manufactures phase I-III clinical supplies in various dosage forms; provides scientific, product development, commercial, and clin...
30 North Jefferson Road
Whippany, NJ 07981
Founded in 2006
Egalet Corporation, Egalet Ltd. and Egalet US Inc. Enters into Drug Product Manufacturing Services Agreement with Halo Pharmaceutical, Inc
Mar 6 17
On February 28, 2017, Egalet Corporation and its wholly-owned subsidiaries, Egalet Ltd. and Egalet US Inc., entered into a Drug Product Manufacturing Services Agreement with Halo Pharmaceutical Inc. pursuant to which Egalet engaged Halo to provide certain services related to the manufacture and supply of ARYMOTM ER tablets for the company's commercial use in the United States. Egalet is obligated to purchase all of its requirements for the product from Halo through 2019, and 75% of its requirements thereafter, subject to certain limited exceptions. Egalet will purchase the product pursuant to binding purchase orders at a fixed price based on dosage strength, with specified percentage rebates for annual volumes of products ordered over a specified amount. In addition, Egalet has agreed to purchase certain minimum amounts of manufacturing and additional services per calendar quarter from Halo over the term of the agreement. If Egalet fails to meet the Quarterly Minimum, it will be required to pay to Halo the resulting shortfall. The term of the agreement is five years from the date of Egalet's first firm order for Product. The agreement will automatically extend for successive two-year renewal terms unless either party gives six months prior written notice of its intention to terminate the agreement. The agreement also contains customary representations, warranties and covenants, including with respect to the ownership of any intellectual property created pursuant to the agreement, as well as provisions relating to ordering, payment and shipping terms, regulatory matters, reporting obligations, indemnity, confidentiality and other matters.
Halo Pharmaceutical Inc. Announces Management Appointments
Aug 26 15
Halo Pharmaceutical Inc. announced the appointments of Lee Karras as its Chief Executive Officer and Barry Lederman as its Chief Financial Officer. Lee Karras is an established pharmaceutical business executive with over twenty five years of healthcare industry related experience. Prior to joining the company, Lee held executive leadership roles in several businesses. Most recently he was President of IBA Molecular North America. Barry Lederman has extensive financial and international pharmaceutical experience, having led teams of several public and private companies with global operations. Prior to joining the company, he served as the Vice President and CFO for Eisai Inc.